Special Issue

Hantavirus

Message from the Guest Editors

Prototype hantavirus was isolated in the 1970s as the causative agent of rodent-borne zoonotic diseases, including hemorrhagic fever with renal syndrome (HFRS). Since rodent-borne orthohantaviruses are highly pathogenic to humans, dealing with these viruses remains an important issue. On the other hand, Thottapalayam virus, which was isolated from a shrew in India in the 1950s, was revealed to be a member of the family Hantaviridae. Furthermore, in recent years, hantaviruses have been discovered from shrews, bats, reptiles, and fish. Information on these many novel wildlife-derived hantaviruses of unknown pathogenicity is needed because they can be a cause of a novel pandemic such as the pandemic caused by SARS2 coronavirus. Addressing the challenges of hantaviruses requires a wide range of virological studies related to epidemiology, biology, cell biology, immunology, pharmaceutics, and numerous academic fields. This Special issue covers a wide range of issues related to hantaviruses and aims to boost the foundation of hantavirus virology.

Guest Editors

Prof. Dr. Kumiko Yoshimatsu

Graduate School of Infectious Diseases, Hokkaido University, Sapporo 060-0818, Japan

Prof. Dr. Hiroaki Kariwa

Laboratory of Public Health, Department of Preventive Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan

Deadline for manuscript submissions

closed (20 December 2021)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/63945

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).